Multi-target-Directed Ligands To Combat Neurodegenerative Diseases

Network biology: understanding the cell's functional organization

Barabási, A.-L., & Oltvai, Z. N. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1272 · Cited by 7,903 · see citing works

Mitochondrial Dysfunction and Oxidative Stress in Neurodegenerative Diseases

Lin, M. T., & Beal, M. F. (2006) · Nature · doi:10.1038/nature05292 · Cited by 6,455 · see citing works

The cholinergic hypothesis of geriatric memory dysfunction

Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545 · see citing works

Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide

Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744 · see citing works

Cell Death

Danial, N. N., & Korsmeyer, S. J. (2004) · Cell · doi:10.1016/s0092-8674(04)00046-7 · Cited by 4,651 · see citing works

Can the pharmaceutical industry reduce attrition rates?

Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167 · see citing works

Motor Neuron Degeneration in Mice that Express a Human Cu,Zn Superoxide Dismutase Mutation

Gurney, M. E., Pu, H., Chiu, A. Y., Dal Canto, M. C., Polchow, C. Y., Alexander, D. D., Caliendo, J., Hentati, A., Kwon, Y. W., Deng, H.-X., et al. (1994) · Science · doi:10.1126/science.8209258 · Cited by 4,143 · see citing works

Alzheimer’s disease

Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134 · see citing works

Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases

Bucciantini, M., Giannoni, E., Chiti, F., Baroni, F., Formigli, L., Zurdo, J., Taddei, N., Ramponi, G., Dobson, C. M., & Stefani, M. (2002) · Nature · doi:10.1038/416507a · Cited by 2,434 · see citing works

Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy

Cuervo, A. M., Stefanis, L., Fredenburg, R., Lansbury, P. T., & Sulzer, D. (2004) · Science · doi:10.1126/science.1101738 · Cited by 2,024 · see citing works

Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death

Arrasate, M., Mitra, S., Schweitzer, E. S., Segal, M. R., & Finkbeiner, S. (2004) · Nature · doi:10.1038/nature02998 · Cited by 1,979 · see citing works

Cholinesterase inhibitors for Alzheimer's disease

Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906 · see citing works

Oxidative stress in neurodegeneration: Cause or consequence?

Andersen, J. K. (2004) · Nature Medicine · doi:10.1038/nrn1434 · Cited by 1,869 · see citing works

Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective

Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849 · see citing works

Iron, brain ageing and neurodegenerative disorders

Zecca, L., Youdim, M. B. H., Riederer, P., Connor, J. R., & Crichton, R. R. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1537 · Cited by 1,801 · see citing works

Copper Homeostasis and Neurodegenerative Disorders (Alzheimer's, Prion, and Parkinson's Diseases and Amyotrophic Lateral Sclerosis)

Gaggelli, E., Kozlowski, H., Valensin, D., & Valensin, G. (2006) · Chemical Reviews · doi:10.1021/cr040410w · Cited by 1,729 · see citing works

P <scp>ROTOFIBRILS</scp> , P <scp>ORES</scp> , F <scp>IBRILS, AND</scp> N <scp>EURODEGENERATION</scp> : Separating the Responsible Protein Aggregates from The Innocent Bystanders

Caughey, B., & Lansbury, P. T. (2003) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.26.010302.081142 · Cited by 1,650 · see citing works

Unfolding the role of protein misfolding in neurodegenerative diseases

Soto, C. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1007 · Cited by 1,506 · see citing works

Selective loss of glial glutamate transporter GLT‐1 in amyotrophic lateral sclerosis

Rothstein, J. D., Van Kammen, M., Levey, A. I., Martin, L. J., & Kuncl, R. W. (1995) · Annals of Neurology · doi:10.1002/ana.410380114 · Cited by 1,471 · see citing works

An english translation of alzheimer’s 1907 paper, “über eine eigenartige erkankung der hirnrinde”

Stelzmann, R. A., Norman Schnitzlein, H., & Reed Murtagh, F. (1995) · Clinical Anatomy · doi:10.1002/ca.980080612 · Cited by 1,455 · see citing works

ABAD Directly Links Aß to Mitochondrial Toxicity in Alzheimer's Disease

Lustbader, J. W., Cirilli, M., Lin, C., Xu, H. W., Takuma, K., Wang, N., Caspersen, C., Chen, X., Pollak, S., Chaney, M., et al. (2004) · Science · doi:10.1126/science.1091230 · Cited by 1,303 · see citing works

Designed Multiple Ligands. An Emerging Drug Discovery Paradigm

Morphy, R., & Ranković, Z. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058225d · Cited by 1,237 · see citing works

Aggregation and Motor Neuron Toxicity of an ALS-Linked SOD1 Mutant Independent from Wild-Type SOD1

Bruijn, L. I., Houseweart, M. K., Kato, S., Anderson, K. L., Anderson, S., Ohama, E., Reaume, A. G., Scott, R. W., & Cleveland, D. W. (1998) · Science · doi:10.1126/science.281.5384.1851 · Cited by 1,231 · see citing works

Importance of SE-glutathione peroxidase, catalase, and CU/ZN-SOD for cell survival against oxidative stress

Michiels, C., Raes, M. J., Toussaint, O., & Remacle, J. (1994) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(94)90079-5 · Cited by 1,194 · see citing works

Decreased Glutamate Transport by the Brain and Spinal Cord in Amyotrophic Lateral Sclerosis

Rothstein, J. D., Martin, L. J., & Kuncl, R. W. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205283262204 · Cited by 1,180 · see citing works

Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

Roth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155 · see citing works

Molecular biology of amyotrophic lateral sclerosis: insights from genetics

Pasinelli, P., & Brown, R. H. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1971 · Cited by 1,107 · see citing works

Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines

Panov, A. V., Gutekunst, C.-A., Leavitt, B. R., Hayden, M. R., Burke, J. R., Strittmatter, W. J., & Greenamyre, J. T. (2002) · Nature Neuroscience · doi:10.1038/nn884 · Cited by 1,030 · see citing works

[241 Total antioxidant status in plasma and body fluids

Rice-Evans, C. A., & Miller, N. J. (1994) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/0076-6879(94)34095-1 · Cited by 991 · see citing works

Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease

El Khoury, J., Toft, M., Hickman, S. E., Means, T. K., Terada, K., Geula, C., & Luster, A. D. (2007) · Nature Medicine · doi:10.1038/nm1555 · Cited by 915 · see citing works

Conformational disease

Carrell, R. W., & Lomas, D. A. (1997) · The Lancet · doi:10.1016/s0140-6736(97)02073-4 · Cited by 811 · see citing works

The efficiency of multi-target drugs: the network approach might help drug design

CSERMELY, P., AGOSTON, V, & PONGOR, S. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.02.007 · Cited by 803 · see citing works

Therapeutic approaches to protein-misfolding diseases

Cohen, F. E., & Kelly, J. W. (2003) · Nature · doi:10.1038/nature02265 · Cited by 792 · see citing works

Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction

Devi, L., Prabhu, B. M., Galati, D. F., Avadhani, N. G., & Anandatheerthavarada, H. K. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1469-06.2006 · Cited by 792 · see citing works

Association of coffee and caffeine intake with the risk of Parkinson disease

Ross, G. W. (2000) · JAMA · doi:10.1001/jama.283.20.2674 · Cited by 778 · see citing works

Multicomponent therapeutics for networked systems

Keith, C. T., Borisy, A. A., & Stockwell, B. R. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1609 · Cited by 769 · see citing works

From magic bullets to designed multiple ligands

Morphy, R., Kay, C., & Ranković, Z. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03163-0 · Cited by 731 · see citing works

Vesicle Permeabilization by Protofibrillar α-Synuclein: Implications for the Pathogenesis and Treatment of Parkinson's Disease

Volles, M. J., Lee, S., Rochet, J., Shtilerman, M. D., Ding, T. T., Kessler, J. C., & Lansbury, P. T. (2001) · Biochemistry · doi:10.1021/bi0102398 · Cited by 682 · see citing works

Prospective Study of Caffeine Consumption and Risk of Parkinson’s Disease in Men and Women

Ascherio, A., Zhang, S. M., Hernán, M. A., Kawachi, I., Colditz, G. A., Speizer, F. E., & Willett, W. C. (2001) · Annals of Neurology · doi:10.1002/ana.1052 · Cited by 677 · see citing works

Diagnosis and treatment of Parkinson disease: molecules to medicine

Savitt, J. M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29178 · Cited by 649 · see citing works

Neuroprotection by the Metabolic Antioxidant α-Lipoic Acid

Packer, L., Tritschler, H. J., & Wessel, K. (1997) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(96)00269-9 · Cited by 639 · see citing works

Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis

Rothstein, J. D., Tsai, G. E., Kuncl, R. W., Clawson, L., Cornblath, D. R., Drachman, D. B., Pestronk, A., Stauch, B. L., & Coyle, J. T. (1990) · Annals of Neurology · doi:10.1002/ana.410280106 · Cited by 637 · see citing works

Epigallocatechin-3-gallate (EGCG): Chemical and biomedical perspectives

Nagle, D. G., Ferreira, D., & Zhou, Y. (2006) · Phytochemistry · doi:10.1016/j.phytochem.2006.06.020 · Cited by 630 · see citing works

Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo

Kaur, D., Yantiri, F., Rajagopalan, S., Kumar, J., Mo, J. Q., Boonplueang, R., Viswanath, V., Jacobs, R., Yang, L., Beal, M. F., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00126-0 · Cited by 620 · see citing works

Neuroprotection by Caffeine and A 2A Adenosine Receptor Inactivation in a Model of Parkinson's Disease

Chen, J., Xu, K., Petzer, J. P., Staal, R. G. W., Xu, Y., Beilstein, M. A., Sonsalla, P. K., Castagnoli, K., Castagnoli, N. J., & Schwarzschild, M. A. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-10-j0001.2001 · Cited by 608 · see citing works

Formation of high molecular weight complexes of mutant Cu,Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis

Johnston, J. A., Dalton, M. J., Gurney, M. E., & Kopito, R. R. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.220417997 · Cited by 607 · see citing works

Systems biology and combination therapy in the quest for clinical efficacy

Fitzgerald, J. B., Schoeberl, B., Nielsen, U. B., & Sorger, P. K. (2006) · Nature Chemical Biology · doi:10.1038/nchembio817 · Cited by 570 · see citing works

Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration

Wang, J., Grundke, I., & Iqbal, K. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05226.x · Cited by 553 · see citing works

Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application

Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 549 · see citing works

Alzheimer's β-Amyloid Peptides Compete for Insulin Binding to the Insulin Receptor

Xie, L., Helmerhorst, E., Taddei, K., Plewright, B., van Bronswijk, W., & Martins, R. N. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-10-j0001.2002 · Cited by 542 · see citing works

Cocaine and Amphetamine Increase Extracellular Dopamine in the Nucleus Accumbens of Mice Lacking the Dopamine Transporter Gene

Carboni, E., Spielewoy, C., Vacca, C., Nosten‐Bertrand, M., Bruno Giros, A., & Chiara, G. D. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-09-j0001.2001 · Cited by 535 · see citing works

Acetylcholinesterase: ‘classical’ and ‘non-classical’ functions and pharmacology

Silman, I., & Sussman, J. L. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.01.014 · Cited by 525 · see citing works

beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies.

Bartolini, M., Bertucci, C., Cavrini, V., & Andrisano, V. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01514-9 · Cited by 523 · see citing works

Constitutive Phosphorylation of the Parkinson's Disease Associated α-Synuclein

Okochi, M., Walter, J., Koyama, A., Nakajo, S., Baba, M., Iwatsubo, T., Meijer, L., Kahle, P. J., & Haass, C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.390 · Cited by 521 · see citing works

Serotonin in Aging, Late-Life Depression, and Alzheimer's Disease: The Emerging Role of Functional Imaging

MELTZER, C. C. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00194-2 · Cited by 517 · see citing works

Amyotrophic Lateral Sclerosis-Associated SOD1 Mutant Proteins Bind and Aggregate with Bcl-2 in Spinal Cord Mitochondria

Pasinelli, P., Belford, M. E., Lennon, N. J., Bacskai, B. J., Hyman, B. T., Trotti, D., & Brown, R. H. (2004) · Neuron · doi:10.1016/j.neuron.2004.06.021 · Cited by 506 · see citing works

Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man

Gerlach, M., & Riederer, P. F. (1996) · Journal of Neural Transmission · doi:10.1007/bf01291788 · Cited by 496 · see citing works

Mechanisms of Parkinson's Disease Linked to Pathological α-Synuclein: New Targets for Drug Discovery

Lee, V. M. ‐., & Trojanowski, J. Q. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.026 · Cited by 478 · see citing works

Can we rationally design promiscuous drugs?

HOPKINS, A., MASON, J., & OVERINGTON, J. (2006) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2006.01.013 · Cited by 469 · see citing works

Clinical limits of amyotrophic lateral sclerosis.

Mulder, D. W. (1982) · PubMed · Cited by 444 · see citing works

Conversion to the amyotrophic lateral sclerosis phenotype is associated with intermolecular linked insoluble aggregates of SOD1 in mitochondria

Deng, H., Shi, Y., Furukawa, Y., Zhai, H., Fu, R., Liu, E., Gorrie, G., Khan, M. S., Hung, W.-Y., Bigio, E. H., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602046103 · Cited by 432 · see citing works

Drosophila as a Model for Human Neurodegenerative Disease

Bilen, J., & Bonini, N. M. (2005) · Annual Review of Genetics · doi:10.1146/annurev.genet.39.110304.095804 · Cited by 420 · see citing works

The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy

Gaeta, A., & Hider, R. C. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706416 · Cited by 411 · see citing works

Advances in the treatment of Parkinson's disease

Singh, N., Pillay, V., & Choonara, Y. E. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.11.009 · Cited by 396 · see citing works

Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders

Youdim, M. B. H., & Buccafusco, J. J. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.11.007 · Cited by 382 · see citing works

The role of calcium‐binding proteins in selective motoneuron vulnerability in amyotrophic lateral sclerosis

Alexianu, M. E., Ho, B., Mohamed, A. H., Bella, V. L., Smith, R. G., & Appel, S. H. (1994) · Annals of Neurology · doi:10.1002/ana.410360608 · Cited by 374 · see citing works

Accumulation of Phosphorylated α-Synuclein in Aging Human Brain

Saito, Y., Kawashima, A., Ruberu, N. N., Fujiwara, H., Koyama, S., Sawabe, M., Arai, T., Nagura, H., Yamanouchi, H., Hasegawa, M., et al. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.6.644 · Cited by 351 · see citing works

Multifunctional Activities of Green Tea Catechins in Neuroprotection

Mandel, S. A., Avramovich‐Tirosh, Y., Reznichenko, L., Zheng, H., Weinreb, O., Amit, T., & Youdim, M. B. H. (2005) · Neurosignals · doi:10.1159/000085385 · Cited by 347 · see citing works

Rasagiline [N‐propargyl‐1R(+)‐aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B

Youdim, M. B. H., Gross, A., & Finberg, J. P. M. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703826 · Cited by 342 · see citing works

In Vivo Optical Imaging of Amyloid Aggregates in Brain: Design of Fluorescent Markers

Nesterov, E. E., Skoch, J. M., Hyman, B. T., Klunk, W. E., Bacskai, B. J., & Swager, T. M. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200500845 · Cited by 337 · see citing works

Adenosine A 2A receptor antagonist treatment of Parkinson’s disease

Bara‐Jimenez, W., Sherzai, A. Z., Dimitrova, T. D., Favit, A., Bibbiani, F., Gillespie, M., Morris, M. J., Mouradian, M. M., & Chase, T. N. (2003) · Neurology · doi:10.1212/01.wnl.0000073136.00548.d4 · Cited by 328 · see citing works

Understanding the molecular causes of Parkinson's disease

Wood‐Kaczmar, A., Gandhi, S., & Wood, N. W. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.09.007 · Cited by 327 · see citing works

Playing dirty

Frantz, S. (2005) · Nature · doi:10.1038/437942a · Cited by 322 · see citing works

Novel pharmacological targets for the treatment of Parkinson's disease

Schapira, A. H. V., Bézard, E., Brotchie, J. M., Calon, F., Collingridge, G. L., Ferger, B., Hengerer, B., Hirsch, É. C., Jenner, P. G., Novère, N. G. L., et al. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2087 · Cited by 299 · see citing works

Inhibition of Amyloid β Protein Aggregation and Neurotoxicity by Rifampicin

Tomiyama, T., Shoji, A., Kataoka, K.-I., Suwa, Y., Asano, S., Kaneko, H., & Endo, N. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.12.6839 · Cited by 295 · see citing works

Coumarins Derivatives as Dual Inhibitors of Acetylcholinesterase and Monoamine Oxidase

Brühlmann, C., Ooms, F., Carrupt, P., Testa, B., Catto, M., Leonetti, F., Altomare, C., & Carotti, A. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010894d · Cited by 291 · see citing works

Lipoic acid as a novel treatment for Alzheimer's disease and related dementias

Holmquist, L., Stuchbury, G., Berbaum, K., Muscat, S., Young, S. A., Häger, K., Engel, J., & Münch, G. W. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.07.001 · Cited by 289 · see citing works

Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice

Capsoni, S., Ugolini, G., Comparini, A., Ruberti, F., Berardi, N., & Cattaneo, A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.12.6826 · Cited by 279 · see citing works

Can cell systems biology rescue drug discovery?

Butcher, E. C. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1754 · Cited by 277 · see citing works

Mitochondrial Dysfunction and Oxidative Damage in Alzheimer's and Parkinson's Diseases and Coenzyme Q10 as a Potential Treatment

Beal, M. F. (2004) · Journal of Bioenergetics and Biomembranes · doi:10.1023/b:jobb.0000041772.74810.92 · Cited by 276 · see citing works

3-(4-{[Benzyl(methyl)amino]methyl}phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) Inhibits Both Acetylcholinesterase and Acetylcholinesterase-Induced β-Amyloid Aggregation: A Dual Function Lead for Alzheimer's Disease Therapy

Piazzi, L., Rampa, A., Bisi, A., Gobbi, S., Belluti, F., Cavalli, A., Bartolini, M., Andrisano, V., Valenti, P., & Recanatini, M. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0340602 · Cited by 268 · see citing works

Inhibition of Monoamine Oxidases by Functionalized Coumarin Derivatives: Biological Activities, QSARs, and 3D-QSARs

Gnerre, C., Catto, M., Leonetti, F., Weber, P. B., Carrupt, P., Altomare, C., Carotti, A., & Testa, B. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm001028o · Cited by 262 · see citing works

Alzheimer disease: progress or profit?

Mount, C., & Downton, C. (2006) · Nature Medicine · doi:10.1038/nm0706-780 · Cited by 262 · see citing works

Protein Oxidation and Lipid Peroxidation in Brain of Subjects with Alzheimer's Disease: Insights into Mechanism of Neurodegeneration from Redox Proteomics

Rukhsana Sultana, A., Marzia Perluigi, A., & Butterfield, D. A. (2006) · Antioxidants and Redox Signaling · doi:10.1089/ars.2006.8.2021 · Cited by 261 · see citing works

Role of microglia in the central nervous system's immune response

Streit, W. J., Conde, J. R., Fendrick, S. E., Flanary, B. E., & Mariani, C. L. (2005) · Neurological Research · doi:10.1179/016164105x49463a · Cited by 258 · see citing works

Novel Tacrine−Melatonin Hybrids as Dual-Acting Drugs for Alzheimer Disease, with Improved Acetylcholinesterase Inhibitory and Antioxidant Properties

Rodrı́guez-Franco, M. I., Fernández‐Bachiller, M. I., Pérez, C., Hernández‐Ledesma, B., & Bartolomé, B. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050746d · Cited by 250 · see citing works

Dual Effects of Antioxidants in Neurodegeneration: Direct Neuroprotection against Oxidative Stress and Indirect Protection via Suppression of Gliamediated Inflammation

Wang, J.-Y., Wen, L. L., Huang, Y.-N., Chen, Y.-T., & Ku, M.-C. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206778343109 · Cited by 250 · see citing works

Novel Dual Inhibitors of AChE and MAO Derived from Hydroxy Aminoindan and Phenethylamine as Potential Treatment for Alzheimer's Disease

STERLING, J. J., Herzig, Y., Goren, T., Finkelstein, N., Lerner, D., Goldenberg, W., MISKOLCZI, I., Molnar, S., Rantal, F., Tamás, T., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020120c · Cited by 249 · see citing works

Amyotrophic lateral sclerosis: A proposed mechanism

Okado‐Matsumoto, A., & Fridovich, I. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.132260399 · Cited by 247 · see citing works

Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats

Shachar, D. B., Kahana, N., Kampel, V., Warshawsky, A., & Youdim, M. B. H. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2003.09.005 · Cited by 246 · see citing works

Therapeutic potential of adenosine A2A receptor antagonists in Parkinson's disease

Xu, K., Bastia, E., & Schwarzschild, M. A. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.10.007 · Cited by 244 · see citing works

Structure, folding, and misfolding of Cu,Zn superoxide dismutase in amyotrophic lateral sclerosis

Rakhit, R., & Chakrabartty, A. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.05.004 · Cited by 233 · see citing works

The deamination of dopamine by human brain monoamine oxidase

O’Carroll, A., Fowler, C. J., Phillips, J. P., Tobbia, I., & Tipton, K. F. (1983) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00500765 · Cited by 231 · see citing works

The channel hypothesis of Alzheimer’s disease: current status

Kagan, B. L., Hirakura, Y., Azimov, R., Azimova, R., & Lin, M. (2002) · Peptides · doi:10.1016/s0196-9781(02)00067-0 · Cited by 230 · see citing works

Rational Approach To Discover Multipotent Anti-Alzheimer Drugs

Rosini, M., Andrisano, V., Bartolini, M., Bolognesi, M. L., Hrelia, P., Minarini, A., Tarozzi, A., & Melchiorre, C. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049112h · Cited by 228 · see citing works

A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease

Takeda, A., Loveman, E., Clegg, A. J., Kirby, J., Picot, J., Payne, L., & Green, C. (2005) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1402 · Cited by 227 · see citing works

Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease

Ikeda, K., Kurokawa, M., Aoyama, S., & Kuwana, Y. (2002) · Journal of Neurochemistry · doi:10.1046/j.0022-3042.2001.00694.x · Cited by 224 · see citing works

Design, Synthesis, and Biological Evaluation of Dual Binding Site Acetylcholinesterase Inhibitors: New Disease-Modifying Agents for Alzheimer's Disease

Muñoz-Ruiz, P., Rubio, L., García‐Palomero, E., Dorronsoro, I., del Monte-Millán, M., Valenzuela, R., Usán, P., de Austria, C., Bartolini, M., Andrisano, V., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0503289 · Cited by 221 · see citing works

Therapies for Alzheimer's disease

Melnikova, I. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2314 · Cited by 219 · see citing works

Targeting acetylcholinesterase to treat neurodegeneration

Holzgrabe, U., Kapková, P., Alptüzün, V., Scheiber, J., & Kugelmann, E. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.2.161 · Cited by 219 · see citing works

Novel multifunctional neuroprotective iron chelator‐monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition

Zheng, H., Gal, S., Weiner, L. M., Bar‐Am, O., Warshawsky, A., Fridkin, M., & Youdim, M. B. H. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03340.x · Cited by 215 · see citing works

Rescuing drug discovery: in vivo systems pathology and systems pharmacology

van der Greef, J., & McBurney, R. N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1904 · Cited by 209 · see citing works

Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors

Castro, A., & Martinez, A. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206778792985 · Cited by 207 · see citing works

The Pathobiology of Amyotrophic Lateral Sclerosis: A Proteinopathy?

Strong, M. J., Kesavapany, S., & Pant, H. C. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000173889.71434.ea · Cited by 206 · see citing works

Promiscuous drugs compared to selective drugs (promiscuity can be a virtue)

Mencher, S. K., & Wang, L. G. (2005) · BMC Clinical Pharmacology · doi:10.1186/1472-6904-5-3 · Cited by 205 · see citing works

Fragments, network biology and designing multiple ligands

Morphy, R., & Ranković, Z. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.12.006 · Cited by 204 · see citing works

High Molecular Weight Complexes of Mutant Superoxide Dismutase 1: Age-Dependent and Tissue-Specific Accumulation

Wang, J., Xu, G. M., & Borchelt, D. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0471 · Cited by 196 · see citing works

The Physicochemical Challenges of Designing Multiple Ligands

Morphy, R., & Ranković, Z. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0603015 · Cited by 194 · see citing works

Iron and copper toxicity in diseases of aging, particularly atherosclerosis and Alzheimer's disease.

Brewer, G. J. (2007) · PubMed · Cited by 193 · see citing works

Amyloid Peptide Channels

Kagan, B. L., Azimov, R., & Azimova, R. (2004) · The Journal of Membrane Biology · doi:10.1007/s00232-004-0709-4 · Cited by 186 · see citing works

Novel multifunctional neuroprotective iron chelator‐monoamine oxidase inhibitor drugs for neurodegenerative diseases.<i>In vivo</i>selective brain monoamine oxidase inhibition and prevention of MPTP‐induced striatal dopamine depletion

Gal, S., Zheng, H., Fridkin, M., & Youdim, M. B. H. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03341.x · Cited by 185 · see citing works

Combination Therapy in Alzheimer???s Disease: A Review of Current Evidence

Schmitt, B., Bernhardt, T., Moeller, H.-J., Heuser, I., & Fr??lich, L. (2004) · CNS Drugs · doi:10.2165/00023210-200418130-00001 · Cited by 182 · see citing works

A Small Molecule Targeting the Multifactorial Nature of Alzheimer's Disease

Cavalli, A., Bolognesi, M. L., Capsoni, S., Andrisano, V., Bartolini, M., Margotti, E., Cattaneo, A., Recanatini, M., & Melchiorre, C. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200700256 · Cited by 180 · see citing works

Dysregulation of Cellular Calcium Homeostasis in Alzheimer's Disease: Bad Genes and Bad Habits

Mattson, M. P., & Chan, S. L. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:17:2:205 · Cited by 178 · see citing works

8‐(3‐Chlorostyryl)caffeine (CSC) is a selective A2‐adenosine antagonist in vitro and in vivo

Jacobson, K. A., Nikodijević, O., Padgett, W. L., Gallo‐Rodriguez, C., Maillard, M. C., & Daly, J. W. (1993) · FEBS Letters · doi:10.1016/0014-5793(93)81466-d · Cited by 173 · see citing works

The Role of Tau Phosphorylation in the Pathogenesis of Alzheimers Disease

Mi, K., & Johnson, G. V. W. (2006) · Current Alzheimer Research · doi:10.2174/156720506779025279 · Cited by 166 · see citing works

Metal‐Catalyzed Disruption of Membrane Protein and Lipid Signaling in the Pathogenesis of Neurodegenerative Disorders

Mattson, M. P. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1306.004 · Cited by 162 · see citing works

Metals in our minds: therapeutic implications for neurodegenerative disorders

Doraiswamy, P. M., & Finefrock, A. E. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00809-9 · Cited by 161 · see citing works

Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives

Mandel, S., Weinreb, O., Amit, T., & Youdim, M. B. H. (2005) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.12.027 · Cited by 157 · see citing works

Synthesis, Characterization, and Metal Coordinating Ability of Multifunctional Carbohydrate-Containing Compounds for Alzheimer's Therapy

Storr, T., Merkel, M., Song-Zhao, G. X., Scott, L. E., Green, D. E., Bowen, M. L., Thompson, K. H., Patrick, B. O., Schugar, H. J., & Orvig, C. (2007) · Journal of the American Chemical Society · doi:10.1021/ja068965r · Cited by 156 · see citing works

Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline

Am, O. B., Amit, T., & Youdim, M. B. H. (2003) · Neuroscience Letters · doi:10.1016/j.neulet.2003.10.067 · Cited by 155 · see citing works

Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system

Witkin, J. M., & Nelson, D. L. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.05.001 · Cited by 148 · see citing works

Neuroprotective Effects of (-)-Epigallocatechin-3-gallate in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis

Xu, Z., Chen, S., Li, X., Luo, G., Li, L., & Le, W. (2006) · Neurochemical Research · doi:10.1007/s11064-006-9166-z · Cited by 147 · see citing works

EVIDENCE FOR DOPAMINE DEAMINATION BY BOTH TYPE A AND TYPE B MONOAMINE OXIDASE IN RAT BRAIN in vivo AND FOR THE DEGREE OF INHIBITION OF ENZYME NECESSARY FOR INCREASED FUNCTIONAL ACTIVITY OF DOPAMINE AND 5‐HYDROXYTRYPTAMINE

GREEN, A. R., Mitchell, B., Tordoff, A. F. C., & Youdim, M. B. H. (1977) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1977.tb07506.x · Cited by 146 · see citing works

Alzheimer's APP mangles mitochondria

Lin, M. T., & Beal, M. F. (2006) · Nature Medicine · doi:10.1038/nm1106-1241 · Cited by 143 · see citing works

5‐hydroxytryptamine (5‐HT, serotonin) and Parkinson's disease – opportunities for novel therapeutics to reduce the problems of levodopa therapy

Nicholson, S. L., & Brotchie, J. M. (2002) · European Journal of Neurology · doi:10.1046/j.1468-1331.9.s3.1.x · Cited by 142 · see citing works

Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis

Dedeoglu, A., Cormier, K., Payton, S., Tseitlin, K. A., Kremsky, J. N., Lai, L., Li, X., Moir, R. D., Tanzi, R. E., Bush, A. I., et al. (2004) · Experimental Gerontology · doi:10.1016/j.exger.2004.08.016 · Cited by 141 · see citing works

The Anti‐Parkinson Drug Rasagiline and Its Cholinesterase Inhibitor Derivatives Exert Neuroprotection Unrelated to MAO Inhibition in Cell Culture and in Vivo

Youdim, M. B. H., WADIA, A., Tatton, W. G., & Weinstock, M. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb03656.x · Cited by 140 · see citing works

One‐compound‐multiple‐targets strategy to combat Alzheimer's disease

Zhang, H. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.09.006 · Cited by 139 · see citing works

Propidium-Based Polyamine Ligands as Potent Inhibitors of Acetylcholinesterase and Acetylcholinesterase-Induced Amyloid-β Aggregation

Bolognesi, M. L., Andrisano, V., Bartolini, M., Banzi, R., & Melchiorre, C. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049156q · Cited by 136 · see citing works

SELECTIVE ACETYLENIC ‘SUICIDE’ AND REVERSIBLE INHIBITORS OF MONOAMINE OXIDASE TYPES A AND B

Kalir, A., Sabbagh, A., & Youdim, M. B. H. (1981) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1981.tb16771.x · Cited by 135 · see citing works

Efficient three‐drug cocktail for disease induced by mutant superoxide dismutase

Križ, J., Gowing, G., & Julien, J. (2003) · Annals of Neurology · doi:10.1002/ana.10500 · Cited by 133 · see citing works

General aspects of neurodegeneration

Jellinger, K. A. (2003) · Journal of Neural Transmission. Supplementa · doi:10.1007/978-3-7091-0643-3_7 · Cited by 126 · see citing works

The Wnt pathway, cell-cycle activation and β-amyloid: novel therapeutic strategies in Alzheimer's disease?

Caricasole, A., Copani, A., Caruso, A., Caraci, F., Iacovelli, L., Sortino, M. A., Terstappen, G. C., & Nicoletti, F. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00100-7 · Cited by 126 · see citing works

Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson?s disease and other neurodegenerative diseases

Youdim, M. B. H., Fridkin, M., & Zheng, H. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-004-0143-x · Cited by 123 · see citing works

Multiple signaling events in amyloid β-induced, oxidative stress-dependent neuronal apoptosis

Tamagno, E. (2003) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(03)00244-2 · Cited by 122 · see citing works

An Intersubunit Disulfide Bond Prevents in Vitro Aggregation of a Superoxide Dismutase-1 Mutant Linked to Familial Amytrophic Lateral Sclerosis

Ray, S. S., Nowak, R. J., Strokovich, K., Brown, R. H., Walz, T., & Lansbury, P. T. (2004) · Biochemistry · doi:10.1021/bi030246r · Cited by 121 · see citing works

The importance of propargylamine moiety in the anti‐ Parkinson drug rasagiline and its derivatives for MAPK‐ dependent amyloid precursor protein processing

Yogev‐Falach, M., Amit, T., Bar‐Am, O., & Youdim, M. B. H. (2003) · The FASEB Journal · doi:10.1096/fj.03-0078fje · Cited by 118 · see citing works

8-(3-Chlorostyryl)caffeine May Attenuate MPTP Neurotoxicity through Dual Actions of Monoamine Oxidase Inhibition and A2A Receptor Antagonism

Chen, J., Steyn, S., Staal, R. G. W., Petzer, J. P., Xu, K., der Schyf, C. J. V., Castagnoli, K., Sonsalla, P. K., Castagnoli, N. J., & Schwarzschild, M. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206830200 · Cited by 117 · see citing works

Regional NAD(P)H:quinone oxidoreductase activity in Alzheimer’s disease

SantaCruz, K. S., Yazlovitskaya, E., Collins, J., Johnson, J., & DeCarli, C. (2004) · Neurobiology of Aging · doi:10.1016/s0197-4580(03)00117-9 · Cited by 116 · see citing works

Novel Multipotent Tacrine−Dihydropyridine Hybrids with Improved Acetylcholinesterase Inhibitory and Neuroprotective Activities as Potential Drugs for the Treatment of Alzheimer's Disease

Marco, J. L., Leon, R. M., Rı́os, C. D. L., Guglietta, A., Terencio, J. V., López, M. G., Garcı́a, A. G., & Villarroya, M. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm061047j · Cited by 116 · see citing works

Entacapone in the treatment of Parkinson's disease

Schrag, A. E. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70098-3 · Cited by 116 · see citing works

Antioxidant Properties of 2,3-Dimethoxy-5-methyl- 6-(10-hydroxydecyl)-1,4-benzoquinone (Idebenone)

Mordente, A., Martorana, G. E., Minotti, G., & Giardina, B. (1998) · Chemical Research in Toxicology · doi:10.1021/tx970136j · Cited by 114 · see citing works

Combating Alzheimer's Disease With Multifunctional Molecules Designed for Metal Passivation

Schugar, H. J., Green, D. E., Bowen, M. L., Scott, L. E., Storr, T., Böhmerle, K., Thomas, F. C., Allen, D. D., Lockman, P. R., Merkel, M., et al. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200603866 · Cited by 112 · see citing works

Huntingtin and Mutant SOD1 Form Aggregate Structures with Distinct Molecular Properties in Human Cells

Matsumoto, G., Kim, S., & Morimoto, R. I. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m509201200 · Cited by 112 · see citing works

On the Molecular Basis Linking Nerve Growth Factor (NGF) to Alzheimer’s Disease

Capsoni, S., & Cattaneo, A. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9112-2 · Cited by 109 · see citing works

Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists

Petzer, J. P., Steyn, S., Castagnoli, K., Chen, J., Schwarzschild, M. A., der Schyf, C. J. V., & Castagnoli, N. (2003) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(02)00648-x · Cited by 108 · see citing works

Novel Tacrine Analogues for Potential Use against Alzheimer's Disease: Potent and Selective Acetylcholinesterase Inhibitors and 5-HT Uptake Inhibitors

MKenna, M. T., Proctor, G. R., Young, L., & Harvey, A. L. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm970150t · Cited by 107 · see citing works

Neurochemical aspects on aging and diseases with cognitive impairment

Gottfries, C. G. (1990) · Journal of Neuroscience Research · doi:10.1002/jnr.490270415 · Cited by 107 · see citing works

Comparative studies of enhanced iron-mediated production of hydroxyl radical by glutathione, cysteine, ascorbic acid, and selected catechols

Nappi, A. J., & Vass, E. (1997) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(97)00039-1 · Cited by 105 · see citing works

Iron involvement in neural damage and microgliosis in models of neurodegenerative diseases.

Shoham, S., & Youdim, M. B. H. (2000) · PubMed · Cited by 101 · see citing works

Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor

Maruyama, W., Weinstock, M., Youdim, M. B. H., Nagai, M., & Naoi, M. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(03)00211-8 · Cited by 100 · see citing works

Genes and the Environment in Neurodegeneration

Coppedè, F., Mancuso, M., Siciliano, G., Migliore, L., & Murri, L. (2006) · Bioscience Reports · doi:10.1007/s10540-006-9028-6 · Cited by 99 · see citing works

Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022

Maruyama, W., Akao, Y., Youdim, M. B. H., & Naoi, M. (2000) · Springer eBooks · doi:10.1007/978-3-7091-6301-6_11 · Cited by 98 · see citing works

LRRK2: a common pathway for parkinsonism, pathogenesis and prevention?

Taylor, J. P., Mata, I. F., & Farrer, M. J. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.12.004 · Cited by 93 · see citing works

Synthesis, biological evaluation and molecular modelling of diversely functionalized heterocyclic derivatives as inhibitors of acetylcholinesterase/butyrylcholinesterase and modulators of Ca2+ channels and nicotinic receptors

Marco, J. L., Rı́os, C. D. L., Garcı́a, A. G., Villarroya, M., Carreiras, M. C., Martins, C., Eleutério, A., Morreale, A., Orozco, M., & Luque, F. J. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.02.017 · Cited by 91 · see citing works

A conformational restriction approach to the development of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer's disease

Toda, N., Tago, K., Marumoto, S., Takami, K., Ori, M., Yamada, N., Koyama, K., Naruto, S., Abe, K., Yamazaki, R., et al. (2003) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(03)00452-8 · Cited by 89 · see citing works

Role of proteolysis in polyglutamine disorders

Tarlac, V., & Storey, E. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10746 · Cited by 88 · see citing works

Multifunctional drugs with different CNS targets for neuropsychiatric disorders

der Schyf, C. J. V., Geldenhuys, W. J., & Youdim, M. B. H. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04141.x · Cited by 88 · see citing works

Cholinesterase Inhibitors: Xanthostigmine Derivatives Blocking the Acetylcholinesterase-Induced β-Amyloid Aggregation

Belluti, F., Rampa, A., Piazzi, L., Bisi, A., Gobbi, S., Bartolini, M., Andrisano, V., Cavalli, A., Recanatini, M., & Valenti, P. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049515h · Cited by 87 · see citing works

NAD(P)H:quinone oxidoreductase activity is increased in hippocampal pyramidal neurons of patients with alzheimer’s disease

Wang, Y., Santa–Cruz, K., DeCarli, C., & Johnson, J. A. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00114-7 · Cited by 87 · see citing works

Mitochondrial Inhibition and Oxidative Stress: Reciprocating Players in Neurodegeneration

Zeevalk, G. D., Bernard, L. P., Song, C., Gluck, M. J., & Ehrhart, J. (2005) · Antioxidants and Redox Signaling · doi:10.1089/ars.2005.7.1117 · Cited by 87 · see citing works

Back to the future: the 'old-fashioned' way to new medications for neurodegeneration

Lansbury, P. T. (2004) · Nature Medicine · doi:10.1038/nrn1435 · Cited by 86 · see citing works

Neuroinflammation in the pathogenesis of amyotrophic lateral sclerosis

Weydt, P., & ̈ller, T. M. (2005) · Neuroreport · doi:10.1097/00001756-200504250-00001 · Cited by 84 · see citing works

The Path from Anti Parkinson Drug Selegiline and Rasagiline to Multifunctional Neuroprotective Anti Alzheimer Drugs Ladostigil and M30

Youdim, M. B. H. (2006) · Current Alzheimer Research · doi:10.2174/156720506779025288 · Cited by 84 · see citing works

Oxidative Stress in Neurodegeneration: Mechanisms and Therapeutic Perspectives

Contestabile, B. S. P. A. (2001) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026013394723 · Cited by 83 · see citing works

Theoretical evaluation of flavonoids as multipotent agents to combat Alzheimer's disease

Ji, H., & Zhang, H. (2006) · Journal of Molecular Structure THEOCHEM · doi:10.1016/j.theochem.2006.04.041 · Cited by 82 · see citing works

Inhibition of monoamine oxidase B by analogues of the adenosine A2A receptor antagonist (E)-8-(3-chlorostyryl)caffeine (CSC)

Vlok, N., Malan, S. F., Castagnoli, N., Bergh, J. J., & Petzer, J. P. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.01.011 · Cited by 82 · see citing works

Acetylcholinesterase Noncovalent Inhibitors Based on a Polyamine Backbone for Potential Use against Alzheimer's Disease

Melchiorre, C., Andrisano, V., Bolognesi, M. L., Budriesi, R., Cavalli, A., Cavrini, V., Rosini, M., Tumiatti, V., & Recanatini, M. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm9810452 · Cited by 81 · see citing works

Estrogen, β‐Amyloid Metabolism/Trafficking, and Alzheimer's Disease

Xu, H., Wang, R., Zhang, Y., & Zhang, X. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1386.036 · Cited by 79 · see citing works

The essentiality of Bcl-2, PKC and proteasome–ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline

Youdim, M. B. H., Amit, T., Yogev‐Falach, M., Bar‐Am, O., Maruyama, W., & Naoi, M. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00535-5 · Cited by 78 · see citing works

Abnormal Phosphorylation of Synapsin I Predicts a Neuronal Transmission Impairment in the R6/2 Huntington's Disease Transgenic Mice

Liévens, J.-C. (2002) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2002.1152 · Cited by 78 · see citing works

Screening of Non‐Alkaloidal Natural Compounds as Acetylcholinesterase Inhibitors

Brühlmann, C., Marston, A., Hostettmann, K., Carrupt, P., & Testa, B. (2004) · Chemistry & Biodiversity · doi:10.1002/cbdv.200490064 · Cited by 77 · see citing works

L-Dopa− and Dopamine−(R)-α-Lipoic Acid Conjugates as Multifunctional Codrugs with Antioxidant Properties

Stefano, A. D., Sozio, P., Cocco, A., Iannitelli, A., Santucci, E., Costa, M., Pecci, L., Nasuti, C., Cantalamessa, F., & Pinnen, F. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051145p · Cited by 76 · see citing works

Huntingtin inclusion bodies are iron‐dependent centers of oxidative events

Firdaus, W. J. J., Wyttenbach, A., Giuliano, P., Kretz‐Remy, C., Currie, R. W., & Arrigo, A. (2006) · The FEBS Journal · doi:10.1111/j.1742-4658.2006.05537.x · Cited by 71 · see citing works

Design and Synthesis of Dual Inhibitors of Acetylcholinesterase and Serotonin Transporter Targeting Potential Agents for Alzheimer's Disease

Kogen, H., Toda, N., Tago, K., Marumoto, S., Takami, K., Ori, M., Yamada, N., Koyama, K., Naruto, S., Abe, K., et al. (2002) · Organic Letters · doi:10.1021/ol026418e · Cited by 71 · see citing works

Microglial interaction with β‐amyloid: Implications for the pathogenesis of Alzheimer's disease

Bamberger, M. E., & Landreth, G. E. (2001) · Microscopy Research and Technique · doi:10.1002/jemt.1121 · Cited by 71 · see citing works

Beneficial effects of melatonin in experimental models of Alzheimer disease1

CHENG, Y., Zheng, F., ZHANG, Q.-Z., & ZHANG, J.-T. (2006) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2006.00267.x · Cited by 71 · see citing works

MAO inhibitors and oxidant stress in aging brain tissue

Alper, G. E., Girgin, F. K., Özgönül, M., Menteş, G., & Ersöz, B. (1999) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(98)00035-2 · Cited by 70 · see citing works

Towards a Unifying Hypothesis of Alzheimers Disease: Cholinergic System Linked to Plaques, Tangles and Neuroinflammation

Sivaprakasam, K. (2006) · Current Medicinal Chemistry · doi:10.2174/092986706777935203 · Cited by 68 · see citing works

Prevention and Treatment of Alzheimer Disease and Aging: Antioxidants

Liu, Q., Xie, F., Rolston, R. K., Moreira, P. I., Nunomura, A., Zhu, X., Smith, M. A., & Perry, G. L. (2007) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955707779802552 · Cited by 68 · see citing works

Acetylcholinesterase Inhibitors as a Starting Point Towards Improved Alzheimers Disease Therapeutics

Recanatini, M., & Valenti, P. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043383313 · Cited by 66 · see citing works

Mitochondrial Involvement in Amyotrophic Lateral Sclerosis: Trigger or Target?

Bacman, S. R., Bradley, W. G., & Moraes, C. T. (2006) · Molecular Neurobiology · doi:10.1385/mn:33:2:113 · Cited by 64 · see citing works

Rationale for Combination Therapy With Galantamine and Memantine in Alzheimer's Disease

Grossberg, G. T., Edwards, K. R., & Zhao, Q. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006288735 · Cited by 64 · see citing works

Targets in ALS: designing multidrug therapies

Carrı̀, M. T., Grignaschi, G., & Bendotti, C. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.03.009 · Cited by 63 · see citing works

Acetylcholinesterase, a senile plaque component, affects the fibrillogenesis of amyloid-β-peptides

Alvarez, A. R., Bronfman, F. C., Pérez, C. A., Vicente, M., Garrido, J., & Inestrosa, N. C. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(94)12127-c · Cited by 63 · see citing works

Further Studies on the Interaction of the 5-Hydroxytryptamine3(5-HT3) Receptor with Arylpiperazine Ligands. Development of a New 5-HT3Receptor Ligand Showing Potent Acetylcholinesterase Inhibitory Properties

Cappelli, A., Gallelli, A., Manini, M., Anzini, M., Mennuni, L., Makovec, F., Menziani, M. C., Alcaro, S., Ortuso, F., & Vomero, S. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0493461 · Cited by 62 · see citing works

Preformed β-amyloid fibrils are destabilized by coenzyme Q10 in vitro

Ono, K., Hasegawa, K., Naiki, H., & Yamada, M. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.02.132 · Cited by 59 · see citing works

GENE–ENVIRONMENT INTERACTIONS, NEURONAL DYSFUNCTION AND PATHOLOGICAL PLASTICITY IN HUNTINGTON'S DISEASE

van Dellen, A., Grote, H., & Hannan, A. J. (2005) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2005.04313.x · Cited by 59 · see citing works

γ-Secretase: a complex target for Alzheimer's disease

Lundkvist, J., & Näslund, J. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.10.002 · Cited by 58 · see citing works

Monamine Oxidase Inhibitors

Fernandez, H. H., & Chen, J. J. (2007) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000240956.49315.be · Cited by 58 · see citing works

Dihydrolipoic acid lowers the redox activity of transition metal ions but does not remove them from the active site of enzymes

Suh, J. H., Zhu, B., deSzoeke, E., Frei, B. B., & Hagen, T. M. (2004) · Redox Report · doi:10.1179/135100004225003923 · Cited by 58 · see citing works

Novel modulators of amyloid‐β precursor protein processing

Tang, B. L., & Liou, Y. C. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04215.x · Cited by 57 · see citing works

Integrated treatment approach improves cognitive function in demented and clinically depressed patients

Bragin, V., Chemodanova, M., Dzhafarova, N., Bragin, I., Czerniawski, J. L., & Aliev, G. M. (2005) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/153331750502000103 · Cited by 56 · see citing works

A new strategy to combat Alzheimer’s disease. Combining radical-scavenging potential with metal-protein-attenuating ability in one molecule

Ji, H., & Zhang, H. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.10.047 · Cited by 54 · see citing works

Synthesis, acetylcholinesterase inhibition and neuroprotective activity of new tacrine analogues

Leon, R. M., Marco, J. L., Garcı́a, A. G., & Villarroya, M. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.11.020 · Cited by 54 · see citing works

Search for dual function inhibitors for Alzheimer’s disease: Synthesis and biological activity of acetylcholinesterase inhibitors of pyridinium-type and their Aβ fibril formation inhibition capacity

Kapková, P., Alptüzün, V., Frey, P., Erciyas, E., & Holzgrabe, U. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.08.034 · Cited by 54 · see citing works

Novel tacrine derivatives that block neuronal calcium channels

Rı́os, C. D. L. (2002) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(01)00378-9 · Cited by 54 · see citing works

Pharmacological Characterization of RS-1259, an Orally Active Dual Inhibitor of Acetylcholinesterase and Serotonin Transporter, in Rodents: Possible Treatment of Alzheimer’s Disease

Abe, Y., Aoyagi, A., Hara, T., Abe, K., Yamazaki, R., Kumagae, Y., Naruto, S., Koyama, K., Marumoto, S., Tago, K., et al. (2003) · Journal of Pharmacological Sciences · doi:10.1254/jphs.93.95 · Cited by 51 · see citing works

New multipotent tetracyclic tacrines with neuroprotective activity

Marco, J. L., Leon, R. M., Rı́os, C. D. L., Garcı́a, A. G., López, M. G., & Villarroya, M. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.09.025 · Cited by 51 · see citing works

Metals, oxidative stress and neurodegenerative disorders

Jomová, K., Vondráková, D., Lawson, M. K., & Valko, M. (2010) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-010-0563-x · Cited by 1,053 · see citing works

A perspective on multi‐target drug discovery and design for complex diseases

Ramsay, R. R., Popović-Nikolić, M. R., Nikolic, K. M., Uliassi, E., & Bolognesi, M. L. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0181-2 · Cited by 730 · see citing works

Development of Multifunctional Molecules as Potential Therapeutic Candidates for Alzheimer’s Disease, Parkinson’s Disease, and Amyotrophic Lateral Sclerosis in the Last Decade

Savelieff, M. G., Nam, G., Kang, J., Lee, H. J., Lee, M., & Lim, M. H. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00138 · Cited by 603 · see citing works

Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases

Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554 · see citing works

Crystal structures of human cholinesterases in complex with huprine W and tacrine: elements of specificity for anti-Alzheimer's drugs targeting acetyl- and butyryl-cholinesterase

Nachon, F., Carletti, E., Ronco, C., Trovaslet, M., Nicolet, Y., Jean, L., & Renard, P. (2013) · Biochemical Journal · doi:10.1042/bj20130013 · Cited by 485 · see citing works

Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds

Proschak, E., Stark, H., & Merk, D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00760 · Cited by 498 · see citing works

Polypharmacology – Foe or Friend?

Peters, J. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400856t · Cited by 477 · see citing works

Recent advances in the multitarget‐directed ligands approach for the treatment of Alzheimer's disease

Leon, R. M., Garcı́a, A. G., & Marco, J. L. (2011) · Medicinal Research Reviews · doi:10.1002/med.20248 · Cited by 442 · see citing works

Natural products as a source of Alzheimer's drug leads

Williams, P., Sorribas, A., & Howes, M.-J. R. (2011) · Nat. Prod. Rep. · doi:10.1039/c0np00027b · Cited by 404 · see citing works

Molecular Hybridization as a Tool for Designing Multitarget Drug Candidates for Complex Diseases

Ivasiv, V., Albertini, C., Gonçalves, A. E., Rossi, M., & Bolognesi, M. L. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190619115735 · Cited by 384 · see citing works

Acetylcholinesterase Inhibitors in the Treatment of Neurodegenerative Diseases and the Role of Acetylcholinesterase in their Pathogenesis

Walczak, Ł. J., & Herbet, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179290 · Cited by 351 · see citing works

Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer’s disease

Guzior, N., Wi.eckowska, A., Panek, D., & Malawska, B. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666141106122628 · Cited by 323 · see citing works

Potential Impact of the Multi-Target Drug Approach in the Treatment of Some Complex Diseases

Makhoba, X. H., Viegas, C., Mosa, R. A., Viegas, F. P. D., & Pooe, O. J. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s257494 · Cited by 333 · see citing works

Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms

Zhou, J., Jiang, X., He, S., Jiang, H., Feng, F., Liu, W., Qu, W., & Sun, H. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00017 · Cited by 307 · see citing works

Structure-Based Search for New Inhibitors of Cholinesterases

Bajda, M., Więckowska, A., Hebda, M., Szałaj, N., Sotriffer, C., & Malawska, B. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14035608 · Cited by 279 · see citing works

New Tacrine–4-Oxo-4H-chromene Hybrids as Multifunctional Agents for the Treatment of Alzheimer’s Disease, with Cholinergic, Antioxidant, and β-Amyloid-Reducing Properties

Fernández‐Bachiller, M. I., Pérez, C., Monjas, L., Rademann, J., & Rodrı́guez-Franco, M. I. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201460y · Cited by 271 · see citing works

LC–MS/MS analysis, antioxidant and anticholinergic properties of galanga (Alpinia officinarum Hance) rhizomes

Köse, L. P., Gülçın, İ., Gören, A. C., Namieśnik, J., Ayala, A. L. M., & Gorinstein, S. (2015) · Industrial Crops and Products · doi:10.1016/j.indcrop.2015.05.034 · Cited by 271 · see citing works

Novel Tacrine−8-Hydroxyquinoline Hybrids as Multifunctional Agents for the Treatment of Alzheimer’s Disease, with Neuroprotective, Cholinergic, Antioxidant, and Copper-Complexing Properties

Fernández‐Bachiller, M. I., Pérez, C., González-Muñoz, G. C., Conde, S., López, M. G., Villarroya, M., Garcı́a, A. G., & Rodrı́guez-Franco, M. I. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100329q · Cited by 270 · see citing works

Sulfonamide derivatives as multi-target agents for complex diseases

Apaydın, S., & Török, M. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.06.041 · Cited by 262 · see citing works

Multitarget Drug Discovery and Polypharmacology

Bolognesi, M. L., & Cavalli, A. (2016) · ChemMedChem · doi:10.1002/cmdc.201600161 · Cited by 237 · see citing works

Synthesis, Biological Evaluation, and Molecular Modeling of Donepezil and N-[(5-(Benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine Hybrids as New Multipotent Cholinesterase/Monoamine Oxidase Inhibitors for the Treatment of Alzheimer’s Disease

Bolea, I., Juárez‐Jiménez, J., Rı́os, C. D. L., Chioua, M., Pouplana, R., Luque, F. J., Unzeta, M., Marco, J. L., & Samadi, A. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200853t · Cited by 220 · see citing works

Molecular hybridization: a powerful tool for multitarget drug discovery

Pinheiro, P. D. S. M., Franco, L. S., Montagnoli, T. L., & Fraga, C. A. M. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2322990 · Cited by 224 · see citing works

Multifunctional compounds: Smart molecules for multifactorial diseases

Bansal, Y., & Silakari, O. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.01.060 · Cited by 215 · see citing works

Neglected Tropical Diseases: Multi-Target-Directed Ligands in the Search for Novel Lead Candidates against Trypanosoma and Leishmania

Cavalli, A., & Bolognesi, M. L. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9004835 · Cited by 212 · see citing works

Novel donepezil-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.

Camps, P., Formosa, X., Galdeano, C., Gómez, T., Muñoz-Torrero, D., Scarpellini, M., Viayna, E., Badía, A., Clos, M. V., Camins, A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8001313 · Cited by 194 · see citing works

The discovery of potential acetylcholinesterase inhibitors: A combination of pharmacophore modeling, virtual screening, and molecular docking studies

Lu, S.-H., Wu, J. W., Liu, H.-L., Zhao, J.-H., Liu, K.-T., Chuang, C.-K., Lin, H.-Y., Tsai, W.-B., & Ho, Y. (2011) · Journal of Biomedical Science · doi:10.1186/1423-0127-18-8 · Cited by 204 · see citing works

Antioxidant and acetylcholinesterase inhibition properties of novel bromophenol derivatives

Öztaşkın, N., Çetinkaya, Y., Taslımı, P., Göksu, S., & Gülçın, İ. (2015) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2015.04.006 · Cited by 203 · see citing works

Oxidative Stress in Alzheimer’s Disease: Are We Connecting the Dots?

Rosini, M., Simoni, E., Milelli, A., Minarini, A., & Melchiorre, C. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400970m · Cited by 202 · see citing works

Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer’s Disease

Agis-Torres, A., Sollhuber, M., Fernandez, M., & Sanchez-Montero, J. M. (2014) · Current Neuropharmacology · doi:10.2174/1570159x113116660047 · Cited by 202 · see citing works

Small Molecule Protein–Protein Interaction Inhibitors as CNS Therapeutic Agents: Current Progress and Future Hurdles

Blazer, L. L., & Neubig, R. R. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.151 · Cited by 197 · see citing works

Histamine H3 Receptor Antagonists Go to Clinics

Sander, K., Kottke, T., & Stark, H. (2008) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.31.2163 · Cited by 195 · see citing works

Validation of Size Estimation of Nanoparticle Tracking Analysis on Polydisperse Macromolecule Assembly

Kim, A., Ng, W. B., Bernt, W., & Cho, N. (2019) · Scientific Reports · doi:10.1038/s41598-019-38915-x · Cited by 193 · see citing works

Design and synthesis of tacrine–ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates

Fang, L., Kraus, B., Lehmann, J., Heilmann, J., Zhang, Y., & Decker, M. W. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.03.073 · Cited by 192 · see citing works

Benzofuran-Based Hybrid Compounds for the Inhibition of Cholinesterase Activity, β Amyloid Aggregation, and Aβ Neurotoxicity

Rizzo, S., Rivière, C., Piazzi, L., Bisi, A., Gobbi, S., Bartolini, M., Andrisano, V., Morroni, F., Tarozzi, A., Monti, J., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8002747 · Cited by 191 · see citing works

Rational Multitargeted Drug Design Strategy from the Perspective of a Medicinal Chemist

Li, X., Li, X., Liu, F., Li, S., & Shi, D. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00683 · Cited by 191 · see citing works

Inhibition of Acetylcholinesterase, β-Amyloid Aggregation, and NMDA Receptors in Alzheimer’s Disease: A Promising Direction for the Multi-target-Directed Ligands Gold Rush

Rosini, M., Simoni, E., Bartolini, M., Cavalli, A., Ceccarini, L., Pascu, N., McClymont, D. W., Tarozzi, A., Bolognesi, M. L., Minarini, A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800577j · Cited by 186 · see citing works

Computational Multitarget Drug Design

Zhang, W., Pei, J., & Lai, L. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00491 · Cited by 186 · see citing works

Amyloid cascade in Alzheimer's disease: Recent advances in medicinal chemistry

Mohamed, T., Shakeri, A., & Rao, P. P. N. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.02.049 · Cited by 181 · see citing works

Synthesis and Evaluation of Multi-Target-Directed Ligands against Alzheimer’s Disease Based on the Fusion of Donepezil and Ebselen

Luo, Z., Sheng, J., Sun, Y., Lu, C., Yan, J., Liu, A., Luo, H., Huang, L., & Li, X. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401047q · Cited by 178 · see citing works

Phytochemical content, antioxidant activity, and enzyme inhibition effect ofSalvia eriophoraBoiss. & Kotschy against acetylcholinesterase, α-amylase, butyrylcholinesterase, and α-glycosidase enzymes

Bursal, E., Aras, A., Kılıç, Ö., Taslımı, P., Gören, A. C., & Gülçın, İ. (2019) · Journal of Food Biochemistry · doi:10.1111/jfbc.12776 · Cited by 177 · see citing works

Multi-Target Directed Drugs: A Modern Approach for Design of New Drugs for the treatment of Alzheimer’s Disease

Dias, K. S. T., & Viegas, C. (2014) · Current Neuropharmacology · doi:10.2174/1570159x1203140511153200 · Cited by 174 · see citing works

Pyrano[3,2-c]quinoline−6-Chlorotacrine Hybrids as a Novel Family of Acetylcholinesterase- and β-Amyloid-Directed Anti-Alzheimer Compounds

Camps, P., Formosa, X., Galdeano, C., Muñoz‐Torrero, D., Ramírez, L., Gómez, E., Isambert, N., Lavilla, R., Badı́a, A., Clos, M. V., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900859q · Cited by 174 · see citing works

Inflammation and NF-κB in Alzheimer's Disease and Diabetes

Granic, I., Dolga, A. M., Nijholt, I. M., van Dijk, G., & Eisel, U. L. M. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-0976 · Cited by 174 · see citing works

Bi- or multifunctional opioid peptide drugs

Schiller, P. W. (2009) · Life Sciences · doi:10.1016/j.lfs.2009.02.025 · Cited by 173 · see citing works

From combinations to multitarget-directed ligands: A continuum in Alzheimer’s disease polypharmacology

Albertini, C., Salerno, A., de Sena Murteira Pinheiro, P., & Bolognesi, M. L. (2021) · Medicinal Research Reviews · doi:10.1002/med.21699 · Cited by 179 · see citing works

Antioxidant, antiradical, and anticholinergic properties of cynarin purified from the Illyrian thistle (Onopordum illyricum L.)

Topal, M., Göçer, H., Topal, F., Kalın, P., Köse, L. P., Gülçın, İ., Çakmak, K. C., Küçük, M., Durmaz, L., Gören, A. C., et al. (2015) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2015.1018244 · Cited by 169 · see citing works

Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015)

McHardy, S. F., Wang, H.-Y. L., McCowen, S. V., & Valdez, M. C. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1272571 · Cited by 162 · see citing works

Tacrine–Melatonin Hybrids as Multifunctional Agents for Alzheimer's Disease, with Cholinergic, Antioxidant, and Neuroprotective Properties

Fernández‐Bachiller, M. I., Pérez, C., Campillo, N. E., Paez, J. A., González-Muñoz, G. C., Usán, P., García‐Palomero, E., López, M. G., Villarroya, M., Garcı́a, A. G., et al. (2009) · ChemMedChem · doi:10.1002/cmdc.200800414 · Cited by 160 · see citing works

Multi-target tacrine-coumarin hybrids: Cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease

Xie, S., Wang, X., Jiang, N., Yu, W., Wang, K. D. G., Lan, J., Li, Z., & Kong, L. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.03.040 · Cited by 160 · see citing works

Alzheimer’s Disease, the “One-Molecule, One-Target” Paradigm, and the Multitarget Directed Ligand Approach

Oset‐Gasque, M. J., & Marco‐Contelles, J. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00069 · Cited by 160 · see citing works

Combining Galantamine and Memantine in Multitargeted, New Chemical Entities Potentially Useful in Alzheimer’s Disease

Simoni, E., Daniele, S., Bottegoni, G., Pizzirani, D., Trincavelli, M. L., Goldoni, L., Tarozzo, G., Reggiani, A., Martini, C., Piomelli, D., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3009458 · Cited by 163 · see citing works

Propargylamine-derived multitarget-directed ligands: fighting Alzheimer’s disease with monoamine oxidase inhibitors

Bolea, I., Gella, A., & Unzeta, M. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-012-0948-y · Cited by 158 · see citing works

Minding metals: Tailoring multifunctional chelating agents for neurodegenerative disease

Perez, L. R., & Franz, K. J. (2010) · Dalton Trans. · doi:10.1039/b919237a · Cited by 156 · see citing works

Synthesis and Multitarget Biological Profiling of a Novel Family of Rhein Derivatives As Disease-Modifying Anti-Alzheimer Agents

Viayna, E., Sola, I., Bartolini, M., Simone, A. D., Tapia‐Rojas, C., Serrano, F. G., Sabaté, R., Juárez‐Jiménez, J., Pérez, B., Luque, F. J., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401824w · Cited by 156 · see citing works

Synthesis, biological evaluation and molecular modeling study of novel tacrine–carbazole hybrids as potential multifunctional agents for the treatment of Alzheimer's disease

Thiratmatrakul, S., Yenjai, C., Waiwut, P., Vajragupta, O., Reubroycharoen, P., Tohda, M., & Boonyarat, C. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.01.020 · Cited by 155 · see citing works

Multitarget Drug Design Strategy: Quinone–Tacrine Hybrids Designed To Block Amyloid‑β Aggregation and To Exert Anticholinesterase and Antioxidant Effects

Nepovimová, E., Uliassi, E., Korábečný, J., Peña‐Altamira, E., Samez, S., Pesaresi, A., Garcia, G. E., Bartolini, M., Andrisano, V., Bergamini, C., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5010804 · Cited by 154 · see citing works

Synthesis, molecular docking, acetylcholinesterase and butyrylcholinesterase inhibitory potential of thiazole analogs as new inhibitors for Alzheimer disease

Rahim, F., Javed, M. T., Ullah, H., Wadood, A., Taha, M., Ashraf, M., Qurat‐ul‐Ain, Khan, M. A., Khan, F., Mirza, S., et al. (2015) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2015.08.002 · Cited by 151 · see citing works

Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy

Wen, S., Wang, G., Zhang, Y., Bu, F., Zhang, S., Miller, D. D., Li, W., Ouyang, L., & Wang, Y. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00100 · Cited by 149 · see citing works

Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezil–indolyl hybrids as multipotent cholinesterase/monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease

Bautista‐Aguilera, Ó. M., Esteban, G., Bolea, I., Nikolic, K. M., Agbaba, D., Moraleda, I., Iriepa, I., Samadi, A., Soriano, E., Unzeta, M., et al. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.12.028 · Cited by 144 · see citing works

Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease

Wang, L., Esteban, G., Ojima, M., Bautista‐Aguilera, Ó. M., Inokuchi, T., Moraleda, I., Iriepa, I., Samadi, A., Youdim, M. B. H., Romero, A., et al. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.04.078 · Cited by 143 · see citing works

Site-Activated Multifunctional Chelator with Acetylcholinesterase and Neuroprotective−Neurorestorative Moieties for Alzheimer’s Therapy

Zheng, H., Youdim, M. B. H., & Fridkin, M. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900504c · Cited by 141 · see citing works

Sustainable Drug Discovery of Multi-Target-Directed Ligands for Alzheimer’s Disease

Rossi, M., Freschi, M., Nascente, L. D. C., Salerno, A., Teixeira, S. D. M. V., Nachon, F., Chantegreil, F., Soukup, O., Prchal, L., Malaguti, M., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00048 · Cited by 139 · see citing works

Reconsideration of Anticholinesterase Therapeutic Strategies against Alzheimer’s Disease

Wang, H., & Zhang, H. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00391 · Cited by 140 · see citing works

Emerging therapeutic potentials of dual‐acting MAO and AChE inhibitors in Alzheimer's and Parkinson's diseases

Mathew, B., Parambi, D. G. T., Mathew, G. E., Uddin, M. S., Inasu, S. T., Kim, H., Marathakam, A., Unnikrishnan, M. K., & Carradori, S. (2019) · Archiv der Pharmazie · doi:10.1002/ardp.201900177 · Cited by 139 · see citing works

Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment

Lecoutey, C., Hédou, D., Fréret, T., Giannoni, P., Gaven, F., Since, M., Bouët, V., Ballandonne, C., Corvaisier, S., Malzert‐Fréon, A., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410315111 · Cited by 136 · see citing works

Tacripyrines, the First Tacrine−Dihydropyridine Hybrids, as Multitarget-Directed Ligands for the Treatment of Alzheimer’s Disease

Marco, J. L., Leon, R. M., Rı́os, C. D. L., Samadi, A., Bartolini, M., Andrisano, V., Huertas, Ó., Barril, X., Luque, F. J., Rodrı́guez-Franco, M. I., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801292b · Cited by 136 · see citing works

Alzheimer's disease: new approaches to drug discovery

Bolognesi, M. L., Matera, R., Minarini, A., Rosini, M., & Melchiorre, C. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.04.619 · Cited by 132 · see citing works

Hydroxypyridinones as “privileged” chelating structures for the design of medicinal drugs

Santos, M. A., Marques, S. M., & Chaves, S. (2011) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2011.08.008 · Cited by 130 · see citing works

BACE-1 Inhibitors: From Recent Single-Target Molecules to Multitarget Compounds for Alzheimer’s Disease

Prati, F., Bottegoni, G., Bolognesi, M. L., & Cavalli, A. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00393 · Cited by 132 · see citing works

The biological activities of butyrylcholinesterase inhibitors

Zhou, S., & Huang, G. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112556 · Cited by 132 · see citing works

Salvia cadmica: Phenolic composition and biological activity

Kocak, M. S., Sarıkürkçü, C., Cengiz, M., Kocak, S., Uren, M. C., & Tepe, B. (2016) · Industrial Crops and Products · doi:10.1016/j.indcrop.2016.03.015 · Cited by 131 · see citing works

Mitochondrial dysfunctions, oxidative stress and neuroinflammation as therapeutic targets for neurodegenerative diseases: An update on current advances and impediments

Rehman, M. U., Sehar, N., Dar, N. J., Khan, A., Arafah, A., Rashid, S., Rashid, S. M., & Ganaie, M. A. (2023) · Neuroscience &amp; Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104961 · Cited by 130 · see citing works

Harnessing Polypharmacology with Medicinal Chemistry

Bolognesi, M. L. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00039 · Cited by 129 · see citing works

Tacrine–Trolox Hybrids: A Novel Class of Centrally Active, Nonhepatotoxic Multi-Target-Directed Ligands Exerting Anticholinesterase and Antioxidant Activities with Low In Vivo Toxicity

Nepovimová, E., Korábečný, J., Doležal, R., Babkova, K., Ondřejíček, A., Jun, D., Šepsová, V., Horova, A., Hrabinová, M., Soukup, O., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01325 · Cited by 129 · see citing works

Anti-cholinesterase hybrids as multi-target-directed ligands against Alzheimer’s disease (1998–2018)

Mishra, P., Kumar, A., & Panda, G. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.01.025 · Cited by 128 · see citing works

Multitarget drug discovery for Alzheimer's disease: triazinones as BACE-1 and GSK-3β inhibitors

Prati, F., De Simone, A., Bisignano, P., Armirotti, A., Summa, M., Pizzirani, D., Scarpelli, R., Perez, D. I., Andrisano, V., Perez‐Castillo, A., et al. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201410456 · Cited by 128 · see citing works

Novel Multitarget-Directed Ligands (MTDLs) with Acetylcholinesterase (AChE) Inhibitory and Serotonergic Subtype 4 Receptor (5-HT₄R) Agonist Activities As Potential Agents against Alzheimer’s Disease: The Design of Donecopride

Rochais, C., Lecoutey, C., Gaven, F., Giannoni, P., Hamidouche, K., Hedou, D., Dubost, E., Genest, D., Yahiaoui, S., Freret, T., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00115 · Cited by 129 · see citing works

The State of the Art of Pyrazole Derivatives as Monoamine Oxidase Inhibitors and Antidepressant/Anticonvulsant Agents

Secci, D., Bolasco, A., Chimenti, P., & Carradori, S. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711797636090 · Cited by 124 · see citing works

Versatility of the Curcumin Scaffold: Discovery of Potent and Balanced Dual BACE-1 and GSK-3β Inhibitors

Martino, R. M. C. D., Simone, A. D., Andrisano, V., Bisignano, P., Bisi, A., Gobbi, S., Rampa, A., Fato, R., Bergamini, C., Pérez, D. I., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00894 · Cited by 124 · see citing works

Synthesis and evaluation of 7-substituted coumarin derivatives as multimodal monoamine oxidase-B and cholinesterase inhibitors for the treatment of Alzheimer's disease

Joubert, J., Foka, G. B., Repsold, B. P., Oliver, D. W., Kapp, E., & Malan, S. F. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.09.041 · Cited by 123 · see citing works

Repurposing Doxycycline for Synucleinopathies: Remodelling of α-Synuclein Oligomers towards Non-Toxic Parallel Beta-Sheet Structured Species

González-Lizárraga, F., Socías, S. B., Ávila, C. L., Torres-Bugeau, C. M., Barbosa, L. R. S., Binolfi, A., Sepúlveda-Díaz, J. E., Del-Bel, E., Fernandez, C. O., Papy-Garcia, D., et al. (2017) · Scientific Reports · doi:10.1038/srep41755 · Cited by 119 · see citing works

Computational polypharmacology: a new paradigm for drug discovery

Chaudhari, R. R., Tan, Z., Huang, B., & Zhang, S. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1280024 · Cited by 120 · see citing works

Metabotropic Glutamate Receptors as Targets for Multipotential Treatment of Neurological Disorders

Byrnes, K. R., Loane, D. J., & Faden, A. I. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.10.038 · Cited by 119 · see citing works

Discovery of Multitarget-Directed Ligands against Alzheimer’s Disease through Systematic Prediction of Chemical–Protein Interactions

Fang, J., Li, Y., Liu, R., Pang, X., Li, C., Yang, R., He, Y., Lian, W., Liu, A., & Du, G. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500574n · Cited by 118 · see citing works

The role of fragment-based and computational methods in polypharmacology

Bottegoni, G., Favia, A. D., Recanatini, M., & Cavalli, A. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.08.002 · Cited by 116 · see citing works

Memoquin: A Multi-Target–Directed Ligand as an Innovative Therapeutic Opportunity for Alzheimer's Disease

Bolognesi, M. L., Cavalli, A., & Melchiorre, C. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.10.042 · Cited by 117 · see citing works

Design, Synthesis and Evaluation of Genistein-O-Alkylbenzylamines as Potential Multifunctional Agents for the Treatment of Alzheimer's Disease

Qiang, X., Sang, Z., Yuan, W., Li, Y., Liu, Q., Bai, P., Shi, Y., Ang, W., Tan, Z., & Deng, Y. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.02.045 · Cited by 113 · see citing works

Tacrine-resveratrol fused hybrids as multi-target-directed ligands against Alzheimer's disease

Jerábek, J., Uliassi, E., Guidotti, L., Korábečný, J., Soukup, O., Šepsová, V., Hrabinová, M., Kuča, K., Bartolini, M., Peña‐Altamira, E., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.12.048 · Cited by 113 · see citing works

Benzylpiperidine-Linked Diarylthiazoles as Potential Anti-Alzheimer’s Agents: Synthesis and Biological Evaluation

Shidore, M. M., Machhi, J., Shingala, K., Murumkar, P. R., Sharma, M. K., Agrawal, N., Tripathi, A., Parikh, Z. S., Pillai, P. P., & Yadav, M. R. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00426 · Cited by 113 · see citing works

Tau-Centric Multitarget Approach for Alzheimer’s Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3β and Tau-Aggregation Inhibitors

Gandini, A., Bartolini, M., Tedesco, D., Martínez‐González, L., Roca, C., Campillo, N. E., Zaldívar-Díez, J., Pérez, C., Zuccheri, G., Miti, A., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00610 · Cited by 112 · see citing works

3-Substituted coumarins as dual inhibitors of AChE and MAO for the treatment of Alzheimer's disease

Viña, D., Matos, M. J., Yáñez, M., Santana, L., & Uriarte, E. (2011) · MedChemComm · doi:10.1039/c1md00221j · Cited by 112 · see citing works

Tackling neuroinflammation and cholinergic deficit in Alzheimer's disease: Multi-target inhibitors of cholinesterases, cyclooxygenase-2 and 15-lipoxygenase

AlFadly, E. D., Elzahhar, P. A., Tramarin, A., Elkazaz, S., Shaltout, H. A., Abu-Serie, M. M., Janočková, J., Soukup, O., Ghareeb, D. A., EL‐Yazbi, A. F., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.02.012 · Cited by 108 · see citing works

Navigating the Chemical Space of Multitarget-Directed Ligands: From Hybrids to Fragments in Alzheimer’s Disease

Prati, F., Cavalli, A., & Bolognesi, M. (2016) · Molecules · doi:10.3390/molecules21040466 · Cited by 110 · see citing works

Discovery of a Novel Class of Potent Coumarin Monoamine Oxidase B Inhibitors: Development and Biopharmacological Profiling of 7-[(3-Chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one Methanesulfonate (NW-1772) as a Highly Potent, Selective, Reversible, and Orally Active Monoamine Oxidase B Inhibitor

Pisani, L., Muncipinto, G., Miscioscia, T. F., Nicolotti, O., Leonetti, F., Catto, M., Caccia, C., Salvati, P., Soto‐Otero, R., Méndez‐Álvarez, E., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9010127 · Cited by 106 · see citing works

Discovery of a Potent Dual Inhibitor of Acetylcholinesterase and Butyrylcholinesterase with Antioxidant Activity that Alleviates Alzheimer-like Pathology in Old APP/PS1 Mice

Viayna, E., Coquelle, N., Cieslikiewicz-Bouet, M., Cisternas, P., Oliva, C. A., Sánchez-López, E., Ettcheto, M., Bartolini, M., De Simone, A., Ricchini, M., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01775 · Cited by 106 · see citing works

Glycogen Synthase Kinase 3β: A New Gold Rush in Anti-Alzheimer’s Disease Multitarget Drug Discovery?: Miniperspective

De Simone, A., Tumiatti, V., Andrisano, V., & Milelli, A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00931 · Cited by 110 · see citing works

Dual inhibitors of P-glycoprotein and tumor cell growth: (Re)discovering thioxanthones

Palmeira, A., Vasconcelos, M. H., Paiva, A. M. O., Fernandes, M. X., Pinto, M. M. M., & Sousa, E. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.10.004 · Cited by 106 · see citing works

Codrug: An efficient approach for drug optimization

Das, N., Dhanawat, M., Dash, B., Nagarwal, R. C., & Shrivastava, S. K. (2010) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2010.09.014 · Cited by 105 · see citing works

Effectiveness of the Combination of Memantine Plus Vitamin D on Cognition in Patients With Alzheimer Disease

Annweiler, C., Herrmann, F. R., Fantino, B., Brugg, B., & Beauchet, O. (2012) · Cognitive and Behavioral Neurology · doi:10.1097/wnn.0b013e31826df647 · Cited by 104 · see citing works

Coumarin-dithiocarbamate hybrids as novel multitarget AChE and MAO-B inhibitors against Alzheimer’s disease: Design, synthesis and biological evaluation

He, Q., Liu, J., Lan, J.-S., Ding, J., Sun, Y., Fang, Y., Jiang, N., Yang, Z., Sun, L., Jin, Y., et al. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.09.010 · Cited by 105 · see citing works

Multi-functional Ligands and Molecular Hybridization: Conceptual Aspects and Application in the Innovative Design of Drug Candidate Prototypes for Neurodegenerative Diseases

Silva, M. D. F., Viegas, F. P. D., Gontijo, V. S., Ortiz, C. J. C., Franco, G. D. R. R., Ernesto, J. T., Damásio, C. M., Fonseca, G. P. D. S., Silva, I. M. F., Massuda, L. E., et al. (2023) · Frontiers in clinical drug research. CNS and neurological disorders · doi:10.2174/9789815123319123110003

The chemistry toolbox of multitarget-directed ligands for Alzheimer's disease

Mesiti, F., Chavarria, D., Gaspar, A., Alcaro, S., & Borges, F. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111572 · Cited by 74 · see citing works

Multi-target-directed drugs for neurodegeneration

Melchiorre, C. (2007) · Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)

Designing drugs with multi-target activity: the next step in the treatment of neurodegenerative disorders

Geldenhuys, W. J., & der Schyf, C. J. V. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.744746 · Cited by 59 · see citing works

Advanced Chemometric Modeling Approaches for the Design of Multitarget Drugs Against Neurodegenerative Diseases

Halder, A. K., Moura, A. S., & Cordeiro, M. N. D. S. (2018) · Methods in pharmacology and toxicology · doi:10.1007/7653_2018_14 · Cited by 3 · see citing works